Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Med Phys. 2012 Mar;39(3):1386-409. doi: 10.1118/1.3685447.
Treatment planning tools that use biologically related models for plan optimization and/or evaluation are being introduced for clinical use. A variety of dose-response models and quantities along with a series of organ-specific model parameters are included in these tools. However, due to various limitations, such as the limitations of models and available model parameters, the incomplete understanding of dose responses, and the inadequate clinical data, the use of biologically based treatment planning system (BBTPS) represents a paradigm shift and can be potentially dangerous. There will be a steep learning curve for most planners. The purpose of this task group is to address some of these relevant issues before the use of BBTPS becomes widely spread. In this report, the authors (1) discuss strategies, limitations, conditions, and cautions for using biologically based models and parameters in clinical treatment planning; (2) demonstrate the practical use of the three most commonly used commercially available BBTPS and potential dosimetric differences between biologically model based and dose-volume based treatment plan optimization and evaluation; (3) identify the desirable features and future directions in developing BBTPS; and (4) provide general guidelines and methodology for the acceptance testing, commissioning, and routine quality assurance (QA) of BBTPS.
正在引入使用与生物学相关的模型进行计划优化和/或评估的治疗计划工具，用于临床应用。这些工具中包含各种剂量反应模型和数量以及一系列特定于器官的模型参数。然而，由于各种限制，例如模型和可用模型参数的限制、对剂量反应的不完全理解以及临床数据不足，使用基于生物学的治疗计划系统（BBTPS）代表了一种范式转变，并且可能存在潜在危险。对于大多数规划师来说，这将是一个陡峭的学习曲线。本任务组的目的是在 BBTPS 广泛使用之前解决其中的一些相关问题。在本报告中，作者：1）讨论在临床治疗计划中使用基于生物学的模型和参数的策略、限制、条件和注意事项；2）演示三种最常用的商业上可用的 BBTPS 的实际使用情况，以及基于生物学模型的和基于剂量-体积的治疗计划优化和评估之间的潜在剂量差异；3）确定开发 BBTPS 的理想功能和未来方向；4）为 BBTPS 的验收测试、调试和常规质量保证（QA）提供一般准则和方法。
